<p class="title">A vaccine to prevent infections caused by the deadly mosquito-borne Zika virus-induced immune response and was found to be safe in an early stage trial, Emergent BioSolutions Inc and partner Valneva SE said on Monday.</p>.<p class="bodytext">The vaccine, VLA1601, which was tested in two doses in 67 adult patients, induced the body to produce neutralizing antibodies against the virus, the companies said.</p>.<p class="bodytext">First discovered in 1947, the Zika virus reached epidemic proportions in Brazil in 2015, when thousands of babies were born with birth defects.</p>.<p class="bodytext">However, bringing a vaccine to market has proved difficult, with drug companies including Japan's Takeda Pharmaceutical and Inovio Pharmaceuticals Inc in the race.</p>.<p class="bodytext">Emergent announced an exclusive worldwide license deal for Valneva's Zika vaccine technology in July last year.</p>.<p class="bodytext">Monday's release contained analyses up to day 56 after the first vaccination, with final analysis - at day 208 - expected in the first quarter 2019, the companies said.</p>
<p class="title">A vaccine to prevent infections caused by the deadly mosquito-borne Zika virus-induced immune response and was found to be safe in an early stage trial, Emergent BioSolutions Inc and partner Valneva SE said on Monday.</p>.<p class="bodytext">The vaccine, VLA1601, which was tested in two doses in 67 adult patients, induced the body to produce neutralizing antibodies against the virus, the companies said.</p>.<p class="bodytext">First discovered in 1947, the Zika virus reached epidemic proportions in Brazil in 2015, when thousands of babies were born with birth defects.</p>.<p class="bodytext">However, bringing a vaccine to market has proved difficult, with drug companies including Japan's Takeda Pharmaceutical and Inovio Pharmaceuticals Inc in the race.</p>.<p class="bodytext">Emergent announced an exclusive worldwide license deal for Valneva's Zika vaccine technology in July last year.</p>.<p class="bodytext">Monday's release contained analyses up to day 56 after the first vaccination, with final analysis - at day 208 - expected in the first quarter 2019, the companies said.</p>